Importantly, maximum MM cell killing in vitro was observed at CD38 TriAb concentrations far below serum levels well tolerated in NHP, precluding the side effects associated with potent CD28 stimulation in vivo. The gene discussed is CD38; the disease is Miyoshi myopathy.